Clinical Trials & Research

Researchers at Uppsala University in Sweden are using Integra Biosciences’ PIPETBOY pro pipette controllers with integrated LED lighting to study the physiological function of mast cells and their role in allergic reactions. Their ultimate aim is to develop novel vaccines and therapies to prevent and treat common allergies. Image Credit: Integra Biosciences Related Stories The incidence of

STRATFORD, N.J., March 8, 2023. A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer’s disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate. Their findings

A recent study published in the journal Nature Immunology discovered autoantibodies against chemokines following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The spectrum of coronavirus disease 2019 (COVID-19) manifestation is broad, with convalescent subjects reporting protracted symptoms, a condition termed post-acute sequelae of COVID-19 (PASC) or long COVID. Some evidence suggests the role of

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023. Harbour BioMed (the “Company”), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announces the positive topline results of its phase III clinical trial of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis

In a recent study published in the journal Nature, researchers devised a non-invasive optogenetic and wearable cardiac pacemaker for accurate and specific control of cardiac rhythm for ≤900 beats per minute (bpm), enabled by micro-light-emitting display (LED) harness and systemic channelrhodopsin delivery. Studies have reported an increase in heart rate as a result of anxiety. However,

KING OF PRUSSIA, Pa., Feb. 26, 2023 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL’s investigational first-in-class monoclonal antibody being developed as a long-term prophylactic treatment for patients with hereditary angioedema (HAE). Results from the trial, the

In a recent study published in the Canadian Journal of Cardiology, researchers assessed the association between cardiovascular disease and transportation noise. Study: Too loud to handle?: transportation noise and cardiovascular disease. Image Credit: bibiphoto/Shutterstock The number of studies indicating adverse health impacts as a result of traffic noise is on a steady rise, with cardiovascular

CHICAGO, March 1, 2023. Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of Tourette Syndrome. Participants in the trial receive ecopipam for 12 weeks in the open-label phase of the study. Those with at least a 25% reduction in the Yale Global Tic

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results, published today in the New England Journal of Medicine, are from a research study led

JUPITER, Fla. and BOSTON, Feb. 27, 2023. Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline focused on the treatment of central nervous system (CNS) disorders and rare diseases, today announced topline proof-of-concept preclinical data with its proprietary resveratrol drug product, JOTROL, for Parkinson’s Disease (PD). In collaboration with scientists

A new Rare Diseases Action Plan for England will be published today (Tuesday 28 February) that will ensure those living with these conditions receive better care and treatment, fairer access to testing and have continued support. This builds on the first ever Rare Diseases Action Plan for England published in 2022 which has developed digital

COVINGTON, Ky., Feb. 23, 2023. Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today results from their clinical trial entitled, “An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors (KOURAGE)” have been

Announcing a new publication for Acta Materia Medica journal. The compound 7-ethyl-10-hydroxy-camptothecin (SN38) is a broad-spectrum antitumor agent whose applications are greatly limited by its poor solubility. Therefore, irinotecan, the hydrophilic derived prodrug of SN38, has been developed as the commercial formulation Campto® for colorectal cancer. However, only 1% to 0.1% of irinotecan is converted

PANGYO, South Korea, Feb. 24, 2023. Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidoplenib (SYK inhibitor) in immune thrombocytopenia (ITP) patients who have failed to respond or relapsed after prior therapy. Cevidoplenib was evaluated in a 61-participant randomized, placebo-controlled trial to access its efficacy, safety, tolerability,

Researchers from the University of Queensland have identified that a gene associated with an increased risk of Parkinson’s Disease also contributes to a build-up of cell debris in the brain. Dr Adekunle Bademosi from The Queensland Brain Institute said the discovery could change the focus of Parkinson’s Disease treatment. Our team has found that a

TOKYO, Feb. 22, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating the safety, tolerability and exploratory efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD). The data will

One of the ironies of old age is that the more care and support we need, the harder it can be to access it, given increasing limitations in mobility and independence. Now, research from Japan reports that a governmental initiative to shift healthcare from hospitals into the community is alleviating this burden for an increasing

OSLO, Norway, Feb. 20, 2023. Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs (VA) BRAVO study at the ASCO Genitourinary Cancers Symposium (ASCO GU) which was held February 16-18, 2023 in San Francisco, USA. The clinical data demonstrated a significant decrease in the risk of recurrence &

In a recent study published in the Lancet, researchers performed a systematic review of scientific literature published from inception up to September 31, 2022, that documented the reduction in risk of coronavirus disease 2019 (COVID-19) among individuals with a prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vis-à-vis those with no COVID-19 history. They

PARAMUS, N.J., Feb. 17, 2023 /PRNewswire/ — NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer. The Phase 2b study is an open-label, multicenter, randomized, controlled, 2-arm study to assess the efficacy and safety

Private hospitals were paid around £2bn to help the NHS during the first year of the covid pandemic. But an investigation by The BMJ has found that just 30 of the 200 private hospitals were used to treat patients with covid-19 in April 2020 when the first pandemic wave hit its peak. While there is

SUNNYVALE, Calif., Feb. 16, 2023. Accuray Incorporated announced today that data from the randomized, multicenter trial PACE-A (PACE – Prostate Advances in Comparative Evidence) indicates that stereotactic body radiation therapy (SBRT), in comparison to surgery, better preserves urinary continence and sexual function in men with localized prostate cancer. The study, which was led by The

Dysregulation of serotonin plays a role in many psychiatric disorders, including severe depression and anxiety. In the journal Angewandte Chemie, a research team has now introduced an implantable, electrochemical microsensor that makes it possible to study serotonin dynamics in the brain in real time. In contrast to previous sensors, these are not deactivated by deposition

News Clinical Trials Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients WILLOWBROOK, III., Feb. 13, 2023. Pharmazz, Inc. (“Pharmazz” or the “Company”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that the US

Again and again, studies have shown that exposure to nature can improve human mental health and well-being. A new study from the Cornell Lab of Ornithology dug a little deeper, looking at what kind of nature experiences were associated with a greater sense of well-being during the COVID pandemic. Their findings, published in the journal

SYDNEY, Feb. 9, 2023. Clarity Pharmaceuticals (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial COBRA (NCT05249127)1 for patients with prostate cancer has reached its recruitment target. COBRA (Copper-64 SAR-bisPSMA in Biochemically Recurrent

Melbourne researchers have improved our understanding of how the immune system is regulated to prevent disease, identifying a previously unknown role of ‘natural killer’ (NK) immune cells. The Monash University-led study identified a new group of immune cells, known as tissue-resident memory natural killer (NKRM) cells. NKRM cells limited immune responses in tissues and prevented

BETHESDA, Md., Feb. 10, 2023. A single oral dose of the antibiotic azithromycin can reduce the risk of postpartum sepsis and death among women who deliver vaginally by one-third, according to a large multi-country clinical trial funded by the National Institutes of Health. Only 1.6% of women in the study who received azithromycin during labor